Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Artios, Synnovation and Novartis show mere glimmers of activity.
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.